Core Viewpoint - China Smart Health (00348) announced the resignation of Mr. Lian Weixiong as an independent non-executive director and member of the audit committee, nomination committee, and remuneration committee, effective from August 1, 2025 [1] Summary by Relevant Sections - Resignation Details - Mr. Lian Weixiong has resigned due to the need for more time to handle other business commitments [1] - The resignation will take effect on August 1, 2025 [1]

格隆汇8月1日丨中国智能健康(00348.HK)发布公告，连伟雄因需更多时间处理其他业务承诺，已辞任公 司独立非执行董事及审计委员会、提名委员会及薪酬委员会各自的成员，该辞任自2025年8月1日起生 效。 ...

智通财经APP讯，中国智能健康(00348)发布公告，连伟雄先生因需更多时间处理其他业务承诺，已辞任 公司独立非执行董事及审计委员会、提名委员会及薪酬委员会各自的成员，该辞任自2025年8月1日起生 效。 ...

CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號： 348） 董事名單與其角色和職能 黎學廉先生 曾展鵬先生 董事會設立三個委員會。各董事會成員在這些委員會中所擔任的職位載列如下： 審核委員會 曾展鵬先生（主席） 黎學廉先生 提名委員會 李雄偉先生（主席） 黎學廉先生 曾展鵬先生 勞明韵女士 薪酬委員會 中國智能健康控股有限公司董事（「董事」）會（「董事會」）成員載列如下： 執行董事 李雄偉先生（主席） 張國偉先生（副主席） 梁奕曦先生 勞明韵女士 袁輝霞先生 楊強勝先生 獨立非執行董事 黎學廉先生（主席） 李雄偉先生 曾展鵬先生 香港，二零二五年八月一日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） (股份代號: 348) - 1 - 此外，連先生辭任審計委員會職務後，該委員會的成員減至兩名，未能符合上市規則第 3.21 條的 規定，即審計委員會必須由至少三名非執行董事組成，且大多數為獨立非執行董事。 因此，董事會將按照上市規則的規定，在可行情況下盡快及無論如何於連先生辭任日期起計三個 月內盡力物色合適人選委任為獨立非執行董事，並在必要時任命為審計委員會、提名委員會和薪 酬委員會成員。本公司將於適當時候另行作出公告。 獨立非執行董事辭任 及 董事會委員會組成變更以 及 未能符合上市規則第 3.10(1)、3.10A 及 3.21 條之規定 獨立非執行董事辭任及董事委員會組成變動 中國智能健康控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國智能健康控股有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00348 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 150,000,000,000 | HKD | 0.01 | HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 150,000,000,000 | HKD | 0.01 | HKD | | 1,500,000,000 | ...

Financial Performance - For the year ended December 31, 2024, the Group's turnover decreased by approximately 22% to approximately HK$114 million, down from approximately HK$146 million in FY23[16] - The gross profit margin for FY24 was approximately 33%, compared to approximately 41% in FY23[17] - The overall loss attributable to owners of the Company was approximately HK$40 million, a decrease from HK$135 million in the corresponding year[17] - The gross profit decreased to approximately HK$37 million for the Reporting Year versus approximately HK$60 million in FY23, with a gross profit margin decrease to approximately 33% (FY23: 41%) due to realized losses from investments and decreased interest income[84] - The Group recorded a revenue decrease of approximately 22% from approximately HK$146 million for the year ended 31 December 2023 to approximately HK$114 million for the year ended 31 December 2024[82] - For the year ended 31 December 2024, the Group recorded a net loss of approximately HK$40 million, a significant improvement compared to a loss of approximately HK$135 million in FY23[97] Revenue Breakdown - Revenue from the investment in financial instruments segment decreased from a net gain of approximately HK$6 million in FY23 to a net loss of less than HK$1 million in FY24[21] - Revenue from the Chinese health products segment decreased from approximately HK$130 million in FY23 to approximately HK$113 million in FY24[21] - Revenue from the money lending segment decreased from approximately HK$11 million in FY23 to approximately HK$1 million in FY24[21] - The Chinese health products business segment recorded a loss (before taxation) of approximately HK$6 million in FY24, compared to a profit of HK$3 million in FY23[23] - The traditional Chinese medicine health products segment generated revenue of approximately HK$113 million, a decline from HK$130 million in FY23, and reported a segment loss of approximately HK$6 million compared to a profit of HK$3 million in FY23[26] - The money lending business generated interest income of approximately HK$1 million, down from HK$11 million in FY23, with a segment loss of approximately HK$10 million compared to a loss of HK$116 million in FY23[29] Economic Environment - The challenging economic environment and changing consumer spending patterns significantly impacted the Group's revenue during FY24[24] - The decrease in revenue from the traditional Chinese medicine segment was attributed to a challenging economic environment and changing consumer spending patterns[26] - Local retail business is expected to face challenges due to inflation, recruitment difficulties, and rising operational costs[59] - The Chinese health products business faced challenges in FY24, with high-end product sales declining by approximately 10% to 34% year-over-year[57] Loan Receivables and Credit Losses - As of December 31, 2024, approximately HK$300 million of loan receivables were classified as stage 3 (credit-impaired), representing about 97% of the gross outstanding balance of loan receivables[29] - The expected credit loss (ECL) recognized during FY24 was approximately HK$2 million, significantly reduced from HK$107 million in FY23[34] - The total gross balance of loan receivables as of December 31, 2024, was approximately HK$308.7 million, with a net amount of approximately HK$8.6 million after ECL allowance[37] - The accumulated allowance for Expected Credit Loss (ECL) on the Group's loan receivables amounted to approximately HK$300 million, an increase from approximately HK$294 million as of December 31, 2023[41] - As of December 31, 2024, loan receivables classified as stage 3 represented 97% of the total gross loan receivable balances, up from 95% in FY23[93] Operational Changes and Strategies - The Group maintained eleven outstanding loans as of December 31, 2024, with two classified under stage 1 and nine under stage 3[34] - The Group plans to enhance the promotion of ready-to-eat health products and collaborate with MAME LAB to introduce maternal health care products, targeting local and younger consumers[63] - The Group will launch on the Xiaohongshu social platform in partnership with Weimob to engage directly with consumers, particularly in the PRC market[63] - The management team has implemented cost control measures and enhanced overseas sourcing efficiency to remain competitive[59] - The Group's strategy includes diversifying revenue sources through investments and acquisitions of promising businesses or projects[69] Financial Position and Assets - The Group's total current assets as of 31 December 2024 were approximately HK$113 million, down from HK$140 million as of 31 December 2023[76] - The Group's total assets as of December 31, 2024, were approximately HK$122 million, down from HK$150 million as of December 31, 2023[117] - The Group's borrowings increased to approximately HK$33 million as of December 31, 2024, compared to approximately HK$29 million as of December 31, 2023[70] - The Group's cash and bank balances were approximately HK$10 million as of December 31, 2024, down from approximately HK$14 million as of December 31, 2023[70] - The Group recorded a decrease in shareholders' funds from approximately HK$4 million as of December 31, 2023 to a net liabilities position of approximately HK$18 million as of December 31, 2024[76] Governance and Compliance - The Company has complied with all code provisions set out in the Corporate Governance Code throughout the year ended December 31, 2024[154] - The Board has focused on empowering and developing employees to create long-term value and sustainable growth for shareholders[155] - The Board emphasizes the importance of establishing a culture of integrity, responsibility, collaboration, teamwork, and customer focus to achieve the Company's objectives[163] - The Company is committed to attracting, retaining, and developing talented employees as part of its strategic objectives[163] - The Company received annual written confirmations of independence from all Independent Non-executive Directors for the year ended December 31, 2024[197]

Financial Performance - China Healthwise Holdings Limited reported total revenue of HKD 146,317,000 for the year ending December 31, 2024, compared to HKD 113,575,000 for the previous year, representing a year-over-year increase of 29%[2] - The gross profit for the year was HKD 37,349,000, down from HKD 60,294,000 in the previous year, indicating a decrease of 38%[2] - The net loss for the year was HKD 40,281,000, compared to a net loss of HKD 134,558,000 in the previous year, showing an improvement of 70%[2] - The basic and diluted loss per share was HKD 0.092 (9 cents), improved from HKD 0.1746 (17.46 cents) in the previous year[4] - For the fiscal year ending December 31, 2024, the company reported a net loss of approximately HKD 40,428,000[9] - The total segment loss before tax for the year ending December 31, 2024, was HKD 22,621,000, compared to a loss of HKD 118,344,000 in 2023, indicating an improvement in performance[20] - The company reported a pre-tax loss of HKD 79,374 million, a decrease from HKD 70,759 million in the previous year[28] - The group recorded a total loss attributable to shareholders of about HKD 40 million for the reporting year, compared to approximately HKD 135 million in fiscal year 2023[61] Revenue and Income Sources - Revenue from major business operations for the year is detailed, with specific figures for customer contract income and other sources of income[15][16] - Customer contract income for the year was reported at HKD 112,832 thousand, compared to HKD 129,523 thousand in the previous year, indicating a decline[16] - External customer revenue for the year ending December 31, 2024, was HKD 113,575,000, a decrease from HKD 146,317,000 in 2023, representing a decline of approximately 22.3%[20] - Revenue from the investment financial instruments segment decreased from a net income of approximately HKD 6 million in the previous fiscal year to a net loss of less than HKD 1 million in the current fiscal year[43] - Revenue from the traditional Chinese medicine health products segment decreased from approximately HKD 130 million in the previous fiscal year to about HKD 113 million in the current fiscal year[43] - The traditional Chinese medicine health products segment contributed approximately HKD 113 million in revenue and incurred a loss of about HKD 6 million before tax in the current fiscal year[44] Assets and Liabilities - As of December 31, 2024, the company's total liabilities amounted to approximately HKD 18,838,000[9] - The company's current assets increased from HKD 113,250,000 in 2023 to HKD 139,655,000 in 2024, representing a growth of approximately 23.3%[5] - The total assets for the reporting segments decreased from HKD 146,778,000 in 2023 to HKD 119,557,000 in 2024, reflecting a reduction of about 18.6%[22] - The total liabilities for the reporting segments decreased from HKD 145,272,000 in 2023 to HKD 140,426,000 in 2024, showing a decline of approximately 3.9%[22] - The company's current and non-current borrowings were HKD 32,572,000 and HKD 63,330,000, respectively[9] - The company's total liabilities amounted to approximately HKD 18.38 million as of December 31, 2024[40] - The debt-to-asset ratio is approximately 79%, compared to 67% on December 31, 2023[71] Cash Flow and Financial Management - The company is implementing measures to improve cash flow, including recovering receivables and cost-saving initiatives[9] - The company aims to meet its operational funding needs through improved cash flow from operations[9] - The board has reviewed the group's cash flow forecast, which covers a period of not less than twelve months from the end of the reporting period[10] - The group believes it will have sufficient working capital to meet its operational and financial obligations for the next twelve months[10] - The group is considering measures to improve cash flow, including recovering outstanding receivables and controlling operational costs[13] - The group anticipates challenges in the lending business environment due to expected high HKD interest rates in 2025, which may deter potential borrowers[67] - The group will closely monitor customer repayment habits and develop action plans for debt recovery as risks increase[67] Operational Efficiency and Cost Management - The company reported a significant increase in operating expenses, with general and administrative expenses rising to HKD 26,414,000 from HKD 37,529,000, a decrease of 30%[2] - Employee costs, including director remuneration, totaled HKD 28,966,000 for the year, with HKD 19,408,000 attributed to the herbal health product segment[23] - Selling and distribution expenses increased to approximately HKD 29 million, a rise of about 4% compared to the previous fiscal year[57] - General and administrative expenses decreased to approximately HKD 26 million from HKD 38 million in fiscal year 2023, attributed to cost-saving measures implemented during the reporting year[58] - Financing costs amounted to approximately HKD 8 million, down from about HKD 9 million in fiscal year 2023[59] Credit Risk and Impairment - The company reported a net impairment loss on receivables of HKD 107,469 million, indicating significant credit risk exposure[24] - The expected credit loss provision for receivables was HKD 300,087,000 in 2024, compared to HKD 294,218,000 in 2023, reflecting an increase in provisions[34] - The expected credit loss model provisions for impairment losses decreased significantly to about HKD 2 million from approximately HKD 107 million in the previous fiscal year[60] - The group recognized an expected credit loss of approximately HKD 2 million for the fiscal year, a decrease from HKD 107 million in the previous fiscal year[50] Market Conditions and Strategic Initiatives - The company faced a challenging economic environment, particularly in local retail, which negatively impacted revenue due to changing consumer spending patterns[45] - The local retail business is expected to face challenges due to inflation, hiring difficulties, and rising operational costs, prompting the management team to implement cost control measures[64] - The group plans to enhance the promotion of convenient health food products, including various herbal teas and health supplements, targeting local consumers and the younger demographic[65] - The company plans to enhance its market presence through new product development and strategic investments in the herbal health product segment[21] - The group aims to diversify its revenue sources through investments or acquisitions of businesses with broad prospects[69]

Financial Performance - Revenue for the six months ended June 30, 2024, was HK$60,932,000, compared to HK$47,173,000 for the same period in 2023, representing a 29% increase[4] - Gross profit for the period was HK$19,661,000, up from a gross loss of HK$28,239,000 in the previous year[4] - Total comprehensive loss for the period was HK$28,660,000, an improvement from a loss of HK$31,559,000 in the same period last year, indicating a 9% reduction in losses[5] - Loss attributable to owners of the Company was HK$28,663,000, compared to HK$31,862,000 in the prior year, reflecting a 10% decrease[5] - Basic and diluted loss per share improved to (3.72) cents from (4.14) cents year-over-year[5] - For the six months ended June 30, 2024, the company reported a net cash outflow from operating activities of HK$2,556,000, compared to a net cash inflow of HK$304,000 for the same period in 2023[11] - The total comprehensive loss for the period was HK$28,660,000, with accumulated losses reaching HK$77,311,000 as of June 30, 2024[13] - Loss before income tax for the six months ended 30 June 2024 was HK$28,663, compared to a loss of HK$31,862 for the same period in 2023, indicating an improvement of 6.9%[74] Assets and Liabilities - Non-current assets decreased to HK$7,886,000 as of June 30, 2024, down from HK$10,015,000 at the end of 2023[7] - Current assets totaled HK$101,550,000, a decrease from HK$139,655,000 at the end of 2023, indicating a 27% decline[9] - Current liabilities decreased to HK$132,791,000 from HK$142,953,000, showing a reduction of 7%[9] - The Company reported a net current liabilities position of HK$31,241,000, worsening from HK$3,298,000 at the end of 2023[9] - Total equity showed a capital deficiency of HK$24,262,000 as of June 30, 2024, compared to total equity of HK$4,398,000 at the end of 2023[9] - Cash and cash equivalents at the end of the period decreased to HK$7,005,000 from HK$8,843,000 in the previous year, reflecting a net decrease of HK$1,838,000[11] - The cash and cash equivalents at the beginning of the period were HK$14,421,000, down from HK$16,850,000 in the previous year[11] - As of June 30, 2024, the company had net liabilities of approximately HK$24,262,000, indicating a challenging financial position[16] Cash Flow and Financing - The company is in the process of issuing convertible bonds amounting to HK$16,800,000 and straight bonds of HK$55,000,000 to offset existing convertible loan notes of approximately HK$72,300,000 due in October 2024[16] - The company is actively taking measures to collect loan receivables to improve operating cash flows and financial position[16] - The company reported a net cash outflow from investing activities of HK$141,000 for the six months ended June 30, 2024[11] - The Group's cash flow projections cover a period of not less than twelve months from the end of the reporting period, indicating sufficient capital to finance operations[19] - The directors believe that the Group will have sufficient capital to meet its financial obligations as they fall due within the next twelve months[19] Revenue and Income - Revenue from contracts with customers for the six months ended June 30, 2024, was HK$60,426,000, a decrease of 14% compared to HK$70,259,000 for the same period in 2023[31] - Other income, gains, and losses net for the period amounted to HK$60,932,000, down from HK$80,826,000 in the previous year[31] - The Group recognized an impairment loss on loan receivables of HK$28,334,000 under the expected credit loss model for the period[31] - The Group's interest income from other sources was HK$611,000 for the period[31] - The Group's loan interest income for the period was approximately HK$1 million, a decrease from HK$6 million in 2023, with a segment loss (before taxation) of approximately HK$14 million compared to HK$31 million in 2023[115] Segment Performance - Revenue from the Chinese products segment decreased from approximately HK$70 million in the corresponding period to approximately HK$60 million in the Period[111] - Revenue from the money lending segment decreased from approximately HK$6 million in the corresponding period to approximately HK$1 million in the Period[111] - The segment loss for Chinese health products was approximately HK$2 million, compared to a profit of approximately HK$3 million in the corresponding period[114] - The impairment loss in respect of loan receivables decreased from approximately HK$28 million in the corresponding period to approximately HK$6 million in the Period[113] - The Group's investment in financial instruments reported a segment loss of approximately HK$6 million for the period, compared to a segment profit of approximately HK$4 million in the previous year[122][123] Corporate Governance and Compliance - The Board believes the company has complied with all provisions of the Corporate Governance Code throughout the reporting period[154] - The Audit Committee has reviewed the unaudited condensed interim financial statements for the six months ended June 30, 2024[154] - The company has independent non-executive directors who ensure compliance and governance[156] - The company has made specific inquiries to its Directors regarding compliance with the Model Code for securities transactions[154] Future Plans and Strategies - The Group plans to strengthen the promotion of health care products, including cordyceps sinensis and ginseng, in response to increasing health awareness and an aging population in Hong Kong[128] - The Group aims to develop online sales channels for Chinese health products, capitalizing on the shift to online shopping since the COVID-19 outbreak[129] - Seasonal health and wellness promotions will be conducted regularly to maintain relationships with local customers and attract different customer groups[129] - The Group will introduce coupons on food delivery platforms and collaborate with service providers for live-streaming sales to broaden its customer base[129] - The retail industry faces challenges such as inflation and rising costs, but the Group aims to optimize operations using technology and data, including a potential CRM system[133]

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 60,932,000, a decrease of 24.7% compared to HKD 80,826,000 for the same period in 2023[1] - Gross profit for the same period was HKD 19,661,000, down 41.6% from HKD 33,653,000 year-over-year[1] - The net loss for the six months ended June 30, 2024, was HKD 28,663,000, compared to a net loss of HKD 31,862,000 in the prior year, indicating a 6.9% improvement[2] - Basic and diluted loss per share was HKD 3.72 for the six months ended June 30, 2024, compared to HKD 4.14 for the same period in 2023[2] - Customer contract revenue from the sale of traditional Chinese health products was HKD 60.43 million for the six months ended June 30, 2024, down from HKD 70.26 million for the same period in 2023, representing a decrease of approximately 14.5%[11] - Interest income for the six months ended June 30, 2024, was HKD 611,000, a significant decrease from HKD 5.70 million in the same period of 2023[11] - The group reported a segment loss before tax of HKD (22,150) for the six months ended June 30, 2024, compared to a loss of HKD (23,903) for the same period in 2023, indicating a slight improvement[16] - The group recorded a loss attributable to shareholders of approximately HKD 29 million for the current period, compared to a loss of approximately HKD 32 million for the corresponding period[44] Assets and Liabilities - Total assets as of June 30, 2024, were HKD 132,791,000, a decrease from HKD 142,953,000 as of December 31, 2023[3] - Current liabilities decreased to HKD 101,550,000 from HKD 139,655,000 year-over-year, reflecting a reduction of 27.3%[3] - The company’s equity position showed a net deficit of HKD 24,262,000 as of June 30, 2024, compared to a positive equity of HKD 4,398,000 in the previous year[4] - The total liabilities for the group as of June 30, 2024, were HKD 133,698, a decrease from HKD 145,272 as of June 30, 2023, representing a reduction of about 8%[18] - The group’s total current assets decreased from HKD 39,861 million in December 2023 to HKD 35,057 million in June 2024, representing a decline of approximately 12.5%[30] - The group reported a total of HKD 20,535 million in trade payables and other payables as of June 2024, down from HKD 33,427 million in December 2023, indicating a decrease of approximately 38.5%[34] - The group’s borrowings from securities brokers increased from HKD 15,108 million in December 2023 to HKD 18,944 million in June 2024, reflecting an increase of about 25.5%[35] - The group’s other loans amounted to HKD 10,443 million as of June 2024, compared to HKD 13,614 million in December 2023, showing a decrease of approximately 23.5%[36] Cash Flow and Credit Management - The group is implementing measures to improve cash flow, including recovering receivables and cost-saving initiatives[6] - The board has conducted a detailed review of the group's cash flow forecasts, which cover at least the next 12 months[7] - The group is considering the fair value adjustments of financial assets to improve cash flow[6] - The group has recognized a net loss of HKD 105,000 from the sale of financial instruments for the six months ended June 30, 2024[11] - The group’s cash and cash equivalents decreased to HKD 75 as of June 30, 2024, from HKD 992 as of June 30, 2023, indicating a substantial reduction in liquidity[17] - The aging analysis of trade receivables shows that amounts due within 90 days decreased significantly from HKD 5,517 million in December 2023 to HKD 2,311 million in June 2024, a decline of about 58.2%[33] - The expected credit loss provision for accounts receivable was HKD 299,775,000 for the six months ended June 30, 2024, compared to HKD 294,218,000 for the same period in 2023, indicating an increase of 1.9%[29] - The group assessed the recoverability of receivables, confirming an expected credit loss provision of approximately HKD 300 million, which does not impact the group's cash flow[57] Operational Strategies and Future Plans - The company is committed to improving operational efficiency and exploring new market opportunities to enhance future performance[5] - The group plans to issue convertible bonds of HKD 16.8 million and ordinary bonds of HKD 55 million to offset existing convertible loans of approximately HKD 72.3 million due on October 10, 2024[6] - The group plans to enhance the promotion of health products, particularly traditional Chinese medicine, in response to the increasing demand driven by an aging population in Hong Kong[62] - The group aims to expand online sales channels for health products, capitalizing on the trend towards online shopping since the COVID-19 outbreak[62] - The group is actively attracting corporate clients, successfully securing orders for high-margin health tea bags and nourishing products during the period[63] - The group will enhance its credit policies and risk management strategies to navigate the challenging lending environment[64] Investment and Market Conditions - The group plans to adjust its investment portfolio based on global economic conditions and investor sentiment to improve performance[65] - The investment in financial instruments recorded a segment loss of approximately HKD 6 million for the period, compared to a segment profit of approximately HKD 4 million in 2023, primarily due to realized losses of approximately HKD 5 million[58] - The group reported a significant decrease in the fair value of its investments, with a loss of HKD 5,431 thousand due to fair value changes during the period[58] Dividends and Shareholder Information - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2024, consistent with no dividend declared for the same period in 2023[25] - The average number of ordinary shares used to calculate basic and diluted loss per share remained at 770,480,836 for both periods ended June 30, 2024, and June 30, 2023[26] - Shareholders' equity decreased from approximately HKD 4 million to a net liability position of approximately HKD 24 million due to operating losses during the period[67]